Key result
Milrinone acts primarily via vasodilation in pediatric cardiogenic shock with no consistent evidence of superiority over dobutamine in reducing mortality, hospital stay, or tachyarrhythmia.
Why the study?
Although pediatric guidelines recommend dobutamine as the first-line inodilator in cardiogenic shock, milrinone has become predominant based on theoretical advantages that require critical evaluation against current evidence.
Does milrinone improve hemodynamic or clinical outcomes compared with dobutamine in children with cardiogenic shock?
Does milrinone improve hemodynamic or clinical outcomes compared with dobutamine in children with cardiogenic shock?
Although milrinone is widely favored over guideline-recommended dobutamine in pediatric cardiogenic shock, its action relies mainly on vasodilation and lacks consistent evidence of clinical superiority over dobutamine.
Answers are grounded in this paper and cite their sources.
Questions common milrinone assumptions in pediatric cardiogenic shock; leaves open optimal inotrope strategies pending higher-level evidence.
Cardiogenic shock (CS) is a severe and increasingly common condition in children, representing a global health and economic burden. Inodilators (i.e., vasoactive agents with inotropic and vasodilator effects), most commonly dobutamine and milrinone, are the cornerstone of pharmacological treatment for CS in children. Although pediatric guidelines still recommend dobutamine as the first-line inodilator in CS, the use of milrinone has become predominant in this indication. Milrinone is a phosphodiesterase - 3 inhibitor that is thought to exert inotropic and lusitropic effects and is commonly regarded as offering several theoretical advantages over dobutamine. Based on a critical review of current evidence, we examine here ten myths about milrinone in pediatric CS. The hemodynamic profile of milrinone in CS appears to rely primarily on vasodilation, with limited evidence for clinically meaningful inotropic or lusitropic effects. Current data support a neutral effect on myocardial oxygen consumption and an efficacy in preventing low cardiac output syndrome after pediatric cardiac surgery, while milrinone clearance is reduced in acute kidney injury with unclear clinical significance. However, no consistent evidence demonstrates milrinone's superiority over dobutamine in reducing mortality, length of hospital stay, or tachyarrhythmia, nor its greater efficacy in patients receiving beta-blockers. Its presumed benefits in newborns and in patients with right ventricular failure or pulmonary hypertension remain uncertain and warrant further investigation. What is known: • Milrinone is a phosphodiesterase-3 inhibitor that is thought to exert inotropic and lusitropic effects. • Milrinone has become the preferred inodilator over dobutamine in pediatric cardiogenic shock. What is new: • Milrinone's efficacy appears to stem from vasodilation rather than significant inotropy or lusitropy. • No consistent evidence shows its superiority over dobutamine; further study is warranted.
No takes yet. Share an insight, caveat, or question.
Geroteo et al. (2026) conducted a review in Pediatric cardiogenic shock. Milrinone vs. Dobutamine was evaluated. Milrinone acts primarily via vasodilation in pediatric cardiogenic shock with no consistent evidence of superiority over dobutamine in reducing mortality, hospital stay, or tachyarrhythmia.
Synapse has enriched 10 related papers. Consider them for comparative context: